Study shows promise for detecting mental health problems using smartphone app

smartphone payment
A recent study using Mindstrong Health’s smartphone app showed promise in predicting when mental health issues occur and why they happen. (Image: ipopba/iStock/Getty Images Plus/Getty Images)

A recent study using Mindstrong Health’s app that analyzes smartphone habits showed promise in predicting when mental health issues occur and why they happen.

The study, published in the journal NPJ Digital Medicine, used the smartphone app to collect user activity in 27 volunteers that helped healthcare providers measure a user’s daily habits and detect when those habits deviate. Called digital biomarkers, those habits, when linked with other social and environmental data, provided the information needed to predict mental health issues.

The Mindstrong app captures data on a user’s smartphone activity, including swipes, taps and keystroke events, which was used to identify more than 1,000 distinct digital biomarkers over a 7-day period.

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

“We believe that digital biomarkers are the foundation for measurement-based mental health care, for which there is a massive unmet patient need,” Dr. Paul Dagum, the study’s author and chief executive of Mindstrong, said in a statement. “To provide better mental health care, we need better ways to measure cognitive function and brain health that are quantitative, reproducible, continuous and objective.”

Mindstrong’s technology digests patterns of interaction by tracking which words are used or where and when calls are made and then turns them into objective measures of brain function. The passive app allows for day-to-day monitoring of patients with neuropsychological and neurodegenerative conditions without being intrusive.

Suggested Articles

Janssen is planning its first completely virtual clinical trial, using personal smartphones and wearable devices with no in-person site visits.

Sensyne Health aims to bring its AI tools to America, and it’s enlisting IT giant Cognizant and data infrastructure specialist Agorai to help.

Daré Bioscience added a microchip-based implant to its pipeline and reported data from a pre-pivotal study of a hormone-free contraceptive ring.